Factor X - Bio Products Laboratory
Alternative Names: CoagadexLatest Information Update: 10 Jul 2026
At a glance
- Originator Bio Products Laboratory
- Developer Bio Products Laboratory; Kedrion Biopharma
- Class Antihaemorrhagics; Blood coagulation factors; Coagulants
- Mechanism of Action Blood coagulation factor replacements
-
Orphan Drug Status
Yes - Factor X deficiency
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Factor X deficiency
Most Recent Events
- 29 Jun 2026 Kedrion Biopharma withdrew phase III trial in Factor X deficiency before enrollment due non-safety reasons and the rapidly evolving treatment landscape for AL amyloidosis (NCT06963216)
- 29 Jul 2025 US FDA grants ODD to factor X for the treatment of acquired Factor X Deficiency
- 29 Jul 2025 US FDA provides "Study may proceed letter" for the initiation of phase III trial in Factor X deficiency